Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings
Recursion Pharmaceuticals, Inc. reported Q1 2025 revenue of $14.7M (+6.9% YoY), beat analyst consensus of $14.0M by $785.0K. Diluted EPS came in at $-0.50 (-28.2% YoY), missed the $-0.44 consensus by $0.06.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Recursion Pharmaceuticals, Inc.'s Q1 2025 earnings report.
Recursion Pharmaceuticals, Inc. (RXRX) reported Q1 2025 earnings on May 5, 2025 before market open.
Recursion Pharmaceuticals, Inc. reported revenue of $14.7M and diluted EPS of $-0.50 for Q1 2025.
Revenue beat the consensus estimate of $14.0M by $785.0K. EPS missed the consensus estimate of $-0.44 by $0.06.
Compared to the same quarter a year prior, revenue grew 6.9% from $13.8M a year earlier and diluted EPS declined 28.2% from $-0.39.
You can read the 10-Q periodic report (0001601830-25-000075) directly on SEC EDGAR. The filing index links above go to sec.gov.